|Survey link: https://tapersafer.org/the-protect-study/index|
CEP is a partner organisation of the PROTECT Study, which aims to identify research priorities for reducing and stopping psychiatric drugs.
There are many unanswered questions about the process of reducing and stopping psychiatric medicines (commonly referred to as ‘tapering’) and how best to do it. We think that it is important that future research focuses on the questions that are important to people with lived experience of taking and/or stopping any of these medicines, family members, carers/supporters and healthcare professionals.
The PROTECT study team, in partnership with the James Lind Alliance, has set up this priority setting partnership to identify the Top 10 priorities for future research about reducing and stopping psychiatric medicines. This study could help to change the research agenda which will allow future research to focus on the most important questions.
The study will involve two anonymous online surveys, followed by a workshop with key stakeholders. In the first survey, we ask people to tell us the research questions about reducing and stopping psychiatric medicines that they would like answered by future research. Questions to which the answers are not known will form the basis of the second survey in which people will be asked to rank the questions in order of importance. The Top 10 priorities will be determined at a workshop, involving the Project Steering Group and additional collaborators representing the key stakeholder groups.
If you would like to take the first survey, please click here.
For more information about the James Lind Alliance and the methods we are using, go to https://www.jla.nihr.ac.uk/